Monitor the conference presentations and any subsequent press releases for updates on PMN310's Phase 1b data or pipeline progress; this announcement alone provides no new information to change the investment thesis.
Drug in focus
PMN drug pipeline →PMN310
▲ Bullish Named in this press release- Impact
- Phase
- Phase 1b
- Time to market
- Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
- Next catalyst
- None dated
What to watchThe Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $3.65entry
- T+1 · 11d ago +13.97%α +13.66% · $4.16
- T+5 · 5d ago −4.66%α −7.95% · $3.48
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ProMIS Neurosciences issued a press release announcing its participation in six investor and medical conferences in November and December 2026, including fireside chats and a poster presentation of previously disclosed interim safety and biomarker data from its PRECISE-AD study. The release contains no new financial data, clinical results, or material corporate developments.
Key Facts
- ProMIS will present at Guggenheim, Stifel, UBS, Jefferies, CTAD, and Evercore conferences from Nov 9 to Dec 2, 2026.
- The CTAD poster (P047) covers interim safety and biomarker data from the PRECISE-AD study, previously presented on July 28, 2026.
- No new clinical data, financial results, or business developments were disclosed.
Financial Impact
No financial impact disclosed; routine conference participation with no material news.
Risk Factors
- No new clinical or financial data released; the filing is a routine investor relations update.
- Market cap is small ($27M) and stock is highly volatile (23.2% normal daily move), so even minor news can cause outsized moves.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396211 |
Track record
16 reports on PMN
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +43.16% at T+60 after the Mar 18, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 17, 2026today Press Release Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.25 Now $3.31 +1.85% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $3.29 to $3.31 Now $3.31 +0.61% ▲ +0.61% +2.52% vs SPY
- Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 4/10 Entry $4.16 to $4.05 Now $3.31 −20.43% ▼ −2.64% −5.01% vs SPY
- Nov 5, 202611d ago Press Release Neutral 2/10 Viewing Entry $3.65 to $4.16 Now $3.31 −9.32% ▲ +13.97% +13.66% vs SPY
- Oct 6, 20265w ago 3 Neutral 2/10 Entry $9.12 to $9.15 Now $3.31 −63.71% ▲ +0.33% +0.75% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $9.21 to $9.12 Now $3.31 −64.06% ▼ −0.98% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 3/10 Entry $13.35 to $13.98 Now $3.31 −75.21% ▲ +4.68% +4.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers